Tag
This study establishes transthyretin amyloid cardiomyopathy-specific mitral regurgitation thresholds, revealing lower severity cutoffs than guidelines and enhancing mortality and heart failure hospitalization risk prediction.
Left atrial mechanical dysfunction, particularly atrial electromechanical dissociation and impaired left atrial strain contraction, forecasts increased cerebrovascular events in transthyretin amyloid cardiomyopathy patients even in sinus rh
The EXCALIBUR study reveals significant arrhythmia incidence in cardiac amyloidosis (CA), highlighting subtype-specific arrhythmic profiles linked to myocardial amyloid burden, guiding risk stratification and management.
This article explores a novel, biologically informed framework for monitoring transthyretin amyloid cardiomyopathy progression and treatment, emphasizing mechanism-specific strategies aimed at personalized care.
Acoramidis demonstrates substantial benefits in heart failure-related health status among ATTR-CM patients, significantly improving patient-reported outcomes and supporting its role in modifying disease trajectory.
Acoramidis stabilizes transthyretin and shows kidney-protective effects in transthyretin amyloid cardiomyopathy by reducing eGFR decline and albuminuria, with an initial reversible dip in kidney function associated with improved clinical ou
CARDIO-TTRansform is a global Phase 3 trial evaluating eplontersen’s efficacy and safety in reducing cardiovascular events in transthyretin amyloid cardiomyopathy patients receiving standard care, including TTR stabilizers. With 1,432
In ATTRibute‑CM and its open‑label extension, acoramidis (712 mg twice daily) produced consistent reductions in all‑cause mortality and cardiovascular hospitalizations in both wild‑type and variant ATTR cardiomyopathy, including p.Val142Ile
